Although patients in our study had worse PS, the median PFS in our group was longer compared to patients only receiving anti-tumor therapy, though this did not reach statistical significance.
← all excerpts
Randomized phase III study comparing the first-line chemotherapy regimens in patients with driver mutation-negative advanced non-small cell lung cancer and poor performance status complicated with chronic obstructive pulmonary disease.
1
—
—